A Phase 1 interventional study of Doravirine in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-28.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aimed to investigate the influence of hepatic insufficiency on the pharmacokinetics (PK) of doravirine (MK-1439). In Part 1, PK of doravirine in participants with moderate hepatic insufficiency was compared with that of healthy control subjects matched with regard to mean age and weight. If a clinically meaningful increase in exposure of doravirine was observed in participants with moderate hepatic insufficiency in Part 1, study Part 2 was to evaluate PK of doravirine in participants with mild hepatic insufficiency.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with moderate hepatic insufficiency receive a single oral dose of 100 mg doravirine on Day 1 of Part 1. All participants in this arm were to have moderate hepatic insufficiency based on the Child-Pugh scale.
Drug: Doravirine
Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine on Day 1 of Part 1.
Drug: Doravirine
Participants with mild hepatic insufficiency receive a single oral dose of 100 mg doravirine on Day 1 of Part 1. All participants in this arm were to have mild hepatic insufficiency based on the Child-Pugh scale. This arm was to be enrolled and investigated only if a clinically meaningful increase in exposure of doravirine was observed in participants with moderate hepatic insufficiency in Part 1.
Drug: Doravirine
Following an overnight fast, a single tablet of 100 mg doravirine was be administered orally
Also known as: MK-1439
Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine
Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 6, 12, 24, 48, and 72 hours postdose for all participants and at 96, 120, and 144 hours postdose for participants with hepatic insufficiency
Maximum Observed Plasma Concentration (Cmax) of Doravirine
Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 6, 12, 24, 48, and 72 hours postdose for all participants and at 96, 120, and 144 hours postdose for participants with hepatic insufficiency
Area Under the Plasma Concentration Versus Time Curve Form 0 to 24 Hours (AUC0-24) of Doravirine
Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 6, 12, and 24 hours postdose
Plasma Concentration of Doravirine at 24 Hours (C24)
Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method
Time frame: 24 hours postdose
Part 2 of the study was to enroll participants only if a clinically meaningful increase in exposure of doravirine was observed in participants with moderate hepatic insufficiency in Part 1. Because this was not observed, no participants were enrolled in Part 2 of the study.
| Milestone | Part 1: Participants With Moderate Hepatic Insufficiency | Part 1: Healthy Control Participants | Part 2: Participants With Mild Hepatic Insufficiency |
|---|---|---|---|
| Started | 8 | 8 | 0 |
| Completed | 8 | 8 | 0 |
| Not completed | 0 | 0 | 0 |
Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method
| µM*hr | Part 1: Participants With Moderate Hepatic Insufficiency | Part 1: Healthy Control Participants |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine | 53.9 (41.5 to 70.0) | 54.6 (42.1 to 71.0) |
Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method
| nM | Part 1: Participants With Moderate Hepatic Insufficiency | Part 1: Healthy Control Participants |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Doravirine | 1850 (1420 to 2420) | 2050 (1570 to 2680) |
Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method
| µM*hr | Part 1: Participants With Moderate Hepatic Insufficiency | Part 1: Healthy Control Participants |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve Form 0 to 24 Hours (AUC0-24) of Doravirine | 28.5 (23.4 to 34.8) | 30.6 (25.1 to 37.3) |
Blood was collected for the determination of plasma doravirine using a liquid chromatographic tandem mass spectrometric method
| nM | Part 1: Participants With Moderate Hepatic Insufficiency | Part 1: Healthy Control Participants |
|---|---|---|
| Plasma Concentration of Doravirine at 24 Hours (C24) | 842 (658 to 1080) | 847 (662 to 1080) |
Collected over Up to 14 days after drug administration. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Participants With Moderate Hepatic Insufficiency | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Part 1: Healthy Control Participants | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Event | Part 1: Participants With Moderate Hepatic Insufficiency | Part 1: Healthy Control Participants |
|---|---|---|
| HeadacheNervous system disorders | 0/8 | 2/8 |
| Dry mouthGastrointestinal disorders | 1/8 | 0/8 |
| VomitingGastrointestinal disorders | 1/8 | 0/8 |
| Back painMusculoskeletal and connective tissue disorders | 0/8 | 1/8 |
| Dizziness posturalNervous system disorders | 1/8 | 0/8 |
| SomnolenceNervous system disorders | 1/8 | 0/8 |
All enrolled participants
| Age, Continuous(Years) | Part 1: Participants With Moderate Hepatic Insufficiency | Part 1: Healthy Control Participants | Total |
|---|---|---|---|
| Mean | 59 (54 to 64) | 56 (44 to 63) | 57 (44 to 64) |
| Sex: Female, Male(Participants) | Part 1: Participants With Moderate Hepatic Insufficiency | Part 1: Healthy Control Participants | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 6 | 6 | 12 |
| Child-Pugh Total Score(Participants) | Part 1: Participants With Moderate Hepatic Insufficiency | Part 1: Healthy Control Participants | Total |
|---|---|---|---|
| Total Score = 7 | 2 | 0 | 2 |
| Total Score = 8 | 4 | 0 | 4 |
| Total Score = 9 | 2 | 0 | 2 |
| Weight(kg) | Part 1: Participants With Moderate Hepatic Insufficiency | Part 1: Healthy Control Participants | Total |
|---|---|---|---|
| Mean | 82.0 (55.6 to 119.0) | 79.8 (66.0 to 92.1) | 80.9 (55.6 to 119.0) |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinicaltrials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Mar 2014 to primary completion in May 2014, 1 month.
Results were first posted in Dec 2018, 4 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doravirine